Articles On Alcidion Group (ASX:ALC)

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

    ASX to edge lower after Wall Street pulls back Gold and Bitcoin both touched all time highs Jerome Powell’s testimony later today US time   The ASX is poised to edge lower on Wednesday, tracking movements on Wall Street. At 8am AEDT,...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALC)) – Alcidion Group ((LVH)) – LiveHire Check it out at https://www.fnarena.com/index.php/reporting_season/ Welcome to the FNArena Corporate Results Monitor: Subscrib...

Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial   Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

World Overnight SPI Overnight 6989.00 – 1.00 – 0.01% S&P ASX 200 6977.10 – 20.30 – 0.29% S&P500 4378.38 + 12.40 0.28% Nasdaq Comp 13639.86 + 121.08 0.90% DJIA 34152.60 + 56.74 0.17% S&P500 VIX 14.81 – 0.08 – 0.54%...

World Overnight SPI Overnight 6993.00 – 11.00 – 0.16% S&P ASX 200 6997.40 + 19.20 0.28% S&P500 4365.98 + 7.64 0.18% Nasdaq Comp 13518.78 + 40.50 0.30% DJIA 34095.86 + 34.54 0.10% S&P500 VIX 15.02 + 0.11 0.74% US...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.90% to 6899.70. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify....

ASX200 climbs a very laudable +0.85%  Property stocks (+1.9%) and Health Care (+1.24%) have led the gains Small caps led by Loyalty Lithium, TG6 and Tambourah Metals   The Australian sharemarket has lifted strongly on the first day of the...

The Alcidion Group Ltd (ASX: ALC) share price has returned from its trading halt and sunk deep into the red. At the time of writing, the healthcare technology company's shares are down 27% to a 52-week low of 7.1 cents. What's going on wit...

Atlas Arteria's (ASX:ALC) recent share price decline reflects the material downgrade to distributions receivable by ALX from its key French toll road assets as a result of the proposed new French tax.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AX1)) - Accent Group ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((ALC)) - Alcidion Group ((ALK)) - Alkane Resources ((APA)) - APA Group ((A1N)) - ARN Media ((AIA)) -...

Those investors with small-cap ASX shares in their portfolio have suffered greatly over the past couple of years. Since inflation rocketed, interest rates followed, and Russia stamped into Ukraine, money was pulled out from smaller player...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Frustration can’t begin to describe what it’s like to own certain ASX stocks. The business is excellent — winning new customers, expanding market share — but the stock price just languishes, or even plunges. Even with a long-term horizon,...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Alcidion Group (ALC) announces its Q4 FY23 results, showing strong growth in operating cash flow and new sales The company secures a renewal contract with existing customers and forms a strategic partnership to enhance patient outcomes...

The Alcidion Group Ltd (ASX: ALC) share price is on the move today as shareholders digest the company’s fourth-quarter performance. Shares in the healthcare software provider are 9.1% higher this morning, trading hands at 12 cents apiece....

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

New research identifies Alcidion Group is attaining scale and becoming profitable at an opportune time for healthcare technology demand. -Alcidion Group’s expanded offering in a time of industry demand-Proven business model is scaling and b...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Neurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into UK’s public hospitals   Neurotech to extend Phase 1/2 trial after ethics approval Paediatric neurological disorders specialist, Neurotech...

Wall Street was closed for Memorial Day, European shares were slightly down Beware of “downside correction” in the US market, expert says Rampant short-selling is putting pressure on the oil markets   Wall Street was closed for Memorial D...

It remains a nerve-wracking time for investors in small-cap ASX shares. Inflation is still flying high, interest rates are still heading up, and there is still no certainty as to whether the world will avoid a recession. But, according to...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The tech heavy Nasdaq has officially entered a bull market How long do bulls market usually last? And what will the Nasdaq rally mean for ASX tech stocks?   Well, what do you know? Far from being in a crash-landing recession after the nea...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named as b...

A deep valuation rift has emerged between the larger established tech stocks and the loss-making minnows, with fears that many of the small ‘uns simply will run out of cash in a hostile fund raising climate. Of course the collapse of Silico...

Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half   Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a...

A $1 million portfolio might seem like a far-off dream unless you start by investing an already large sum of money. Though, picking ASX shares with the potential for returns greater than 2,000% over the long term makes this dream much more...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

There have been countless quarterly updates released on Monday. Some have been received well by investors, others less so. Three that haven’t gone down particularly well with investors are summarised below. Here’s why these ASX All Ord...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Alcidion (ALC) has penned an extension to its agreement with Leidos Australia for the additional delivery of a management system to support healthcare services across the Australian Defence Force (ADF)The contract extension is expected to h...

Highlights The ASX 200 benchmark index closed in the green today (December 1), gaining 65.50 points or 0.90% to end at 7,349.70 points. Over the last five days, the index has gained 1.49%, but is down 1.27% for the last year to date....

Alcidion (ALC) signs a three-year agreement with the University Hospital Southampton NHS Foundation Trust (UHS) to implement its Miya Precision IT platformThe $2.8 million contract will see the company deliver a modern, modular electronic p...

Kazia’s positive results published in a Journal Cochlear’s proposed acquisition raised concerns with the ACCC Aldion signs multi-million dollar deal Kazia’s positive results get published Oncology biotech Kazia Therapeutics (ASX:KZA) ann...

According to Oxford Languages, ‘motley’ means “incongruously varied in appearance or character”. But in relation to our Foolish writers, it means they vary greatly with regard to age, risk tolerance, and stage of life as well as in...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...